%0 Journal Article
%A Fernández Montes, A
%A Élez, E
%A Vivancos, A
%A Martínez, N
%A González, P
%A Covela, M
%A de la Cámara, J
%A Cousillas, A
%A Méndez, J C
%A Graña, B
%A Aranda, E
%T Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer.
%D 2022
%U http://hdl.handle.net/10668/21019
%X Some patients with histologically confirmed primary mCRC and mutated RAS reported undetectable RAS mutant clones in plasma after receiving anti-VEGF treatment. The aim was to prospectively assess it with its potential therapeutic implications. RAS mutant genes in solid biopsy (before first-line treatment: FOLFOX/CAPOX + bevacizumab) were compared in liquid biopsy (before second-line treatment: panitumumab + FOLFIRI), using Idylla™ system. Discordant results between solid/liquid biopsies were assessed by the next-generation sequencing (NGS) test (solid/liquid biopsies). Twenty-three patients were assessed (seven had RAS mutant discrepancies between solid/liquid biopsies). The NGS test confirmed that 3/23 (13%) patients had undetectable RAS mutant clones in liquid biopsy and 3/23 (13%) presented discrepancies in solid biopsy (Idylla™ system vs. NGS test). Thirteen percentage of patients had undetectable RAS mutant clones in liquid biopsy after first-line treatment. However, some discrepancies between solid and liquid biopsies have been observed. These results suggest a need to improve accuracy of RAS analyses, especially in solid biopsies.
%K Circulating tumor DNA
%K EGFR inhibitors
%K Liquid biopsy
%K Metastatic colorectal cancer
%K RAS mutant
%~